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ABSTRACT
S
tem cells have thepotentialtolaunchanewareaofmedicine,curingdeadlydiseaseswithcustom-madetissues
and organs. But science and technology may have to take note of regulatory developments, which might impact
if, how, and where that hope will be realized. Until now, no data have been available on the influence of national
human stem cell research legislation on the technological activity in the field of stem cells. In this contribution,
weassesswhetherlegislativeframeworkconditionsaffecttechnologicalactivityinthisfield.Stemcellpatentactivity
(US Patent and Trademark Office [USPTO]/European Patent Office [EPO]) and legislative framework conditions
with respect to human stem cell research have been identified and characterized for the period 1997–2003 for 23
countries. For these countries, differences in human stem cell legislation coincide with differences in technological
productivity. Where obtaining human stem cells from supernumerary embryos is permitted, higher levels of techno-
logicalproductivityforalltypesofstemcellresearchareobserved.Amorepermissivelegislativeapproachtohuman
therapeuticcloningcoincideswithgreateremphasisonembryonicstemcelldevelopmentactivitiesingeneral.These
findings suggest that technology trajectories are modulated by (national) legislative frameworks.
INTRODUCTION
Stem cells are undifferentiated primary cells, found
in all vertebrates and playing important roles in nor-
mal development and regeneration or repair of tissues.
Embryonic stem cells (ESCs) are of particular interest
because of their ability to divide into identical cells or
to differentiate or specialize into many types of body
cells. In contrast, adult stem cells have less replication
capacity. However, human ESCs (hESC) are isolated
from early-stage human embryos, triggering ethical
debates around the world.
As a consequence, no area of biological R&D has
been governed by such an unusual number of diverse
and continually evolving policies as hESCs. At an in-
ternational level (United Nations/UNESCO), various
relevant non-binding declarations, principles, and eth-
ical guidelines have been adopted. Different nations
have installed legislation either restricting or permit-
ting (or even neglecting) this type of research.
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191Europe, whether and how the use of stem cells is
allowed depends on a Member State’s position on
the status of the human embryo. The situation be-
comes more complicated with respect to the avail-
ability of funding for stem cell research. In
Europe, until 2003, no funding could be obtained
from the European Framework program for research
intended to create new hESC lines, except for pro-
jects involving banked hESC cultures. After 2004,
EU funding became available on a project-by-
project basis. Under the current framework program
(FP7), three fields of stem cell research are exclud-
ed: (1) research aimed at human cloning for repro-
ductive purposes; (2) activities intended to modify
the genetic heritage of human beings that could
make such changes heritable; and (3) research
intended to create human embryos solely for the
purpose of research or stem cell procurement. In
earlier years in the US, hESC research did not re-
ceive federal funding because of the Dickey amend-
ment (x128 of Publ L 104-99). From 2000 onward,
the National Institutes of Health (NIH) allowed
funding of pluripotent hESC research. However,
on August 9, 2001, former President George W.
Bush restricted funding for hESC research to the
22 cell lines that existed at that time. It was only
in March 2009 that a US President’s executive
order lifted the ban on US federal funding for
hECS research. That change is now under legal
challenge.
Aside from the scientific challenges stem cell re-
searchers face, the variety of regulatory frameworks
surrounding hESCs creates ethical, economic, polit-
ical, and financial uncertainties and might force re-
searchers to focus more on adult stem cells. The
current study empirically analyzes whether national
research legislation on human stem cells has an im-
pact on the furtherance of stem cell technology.
Previous studies focused mainly on the global pat-
ent landscape of stem cell technology
2 and explored
the influence of human stem cell research legislation
on the productivity of a country in terms of the
number or quality of peer-reviewed research publi-
cations
3 and on the mobility of stem cell research-
ers.
4 These studies indicated that although the US
is clearly leading in the field—in terms of abso-
lute numbers of publications
5—differences in legis-
lation seem to affect the choices of scientists in
terms of topics and hence location.
6 Both Levine
4
and Owen-Smith and McCormick
7 suggested that
the restrictive funding conditions installed in the
US in 2001 might result in American scientists
lagging behind in the field of embryonic stem cell re-
search.
Complementary to these studies, we focus on dif-
ferences in national legal frameworks with respect to
stem cell research and their impact on the technologi-
cal activity of countries. Stated otherwise, to contrib-
ute to the complex societal debate surrounding
human stem cell research, this article analyzes empir-
ically whether different legislative frameworks actual-
ly coincide with differences in technological activity
in human stem cell research.
METHODOLOGY
The study analyzes the relation between the amount
of technological activity, measured by patent indica-
tors, and legislative frameworks pertaining to human
stem cell research from 1997–2003. The unit of anal-
ysis is at the level of national innovation systems,
8
which seems entirely appropriate, given that most
legislative arrangements coincide with national
boundaries.
9
Identifying technology activity in the field
of stem cells
As the analysis of patents is considered one of the
most reliable methods for quantifying the technologi-
cal output of innovation systems,
10 patent documents
from the USPTO and EPO pertaining to stem cells
were identified and analyzed for the period 1997–
2003. All stem cell activity has been taken into consid-
eration, including developments that pertain to non-
human stem cells, as research efforts in this area
are considered relevant and instrumental for human
stem cell R&D activities.
Stem-cell-related patents were identified by apply-
ing a search key developed and validated in con-
2 Bergman K, Graff G. Collaborative IP management for stem
cell research and development. PIPRA Report 2007.
3 Winston RML. Does government regulation inhibit embryon-
ic stem cell research and can it be effective? Cell Stem Cell
2007;1:27–34.
4 Levine AD. Research policy and the mobility of US stem cell
scientists. Nat Biotechnol 2006;24(7).
5 Winston, op. cit.n3 .
6 Levine, op. cit.n4 .
7 Owen-Smith J, McCormick J. An international gap in human
ES cell research. Nat Biotechnol 2006;24:391–2.
8 Freeman C. Technology Policy and Economic Performance.
London: Pinter Publishers, 1987; Lundvall BA. National Sys-
tems of Innovation: Towards a Theory of Innovation and Inter-
active Learning. London: Pinter Publishers, 1992; Nelson RR,
ed. National Innovation Systems: A Comparative Analysis.
New York: Oxford University Press, 1993.
9 Certain US states are adopting legislation mainly prohibiting
reproductive cloning; more differentiated initiatives occurred
only after 2003 and are not included in the current analysis.
10Griliches Z. Patent statistics as economic indicators: a survey,
J Econ Lit 1990;28:1661–707; Grupp H, Schmoch U. Patent
statistics in the age of globalisation: new legal procedures,
new analytical methods, new economic interpretation? Res
Pol’y 1999;28:377–96.
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11 (for full details, see
Gla ¨nzel et al
12).
13 Data were extracted in mid-2005.
As applications are published only after 18 months,
2003 is the most recent year for which complete
data are available. For the EPO, both patent applica-
tions and grants for the years 1997–2003 have been in-
cluded. Although granted US patents were analyzed,
USPTO applications have not been included, as the
USPTO publishes application information only from
2001 onward; in addition, the information published
on USPTO applications contains less applicant ad-
dress information, preventing an exhaustive allocation
to different countries.
In order to analyze the differential effects on em-
bryonic and adult stem cell activity, these patent doc-
uments have been further classified into four
categories:
14 (1) embryonic cells; (2) adult stem
cells; (3) patents where no distinction is made between
adult and embryonic stem cells in the title or abstract;
and (4) techniques for culturing stem cells (e.g., using
different feeder layers, growth factors, and hormones).
In a subsequent step, patent documents have been
assigned to countries on the basis of the nationality
of the applicants, as applicants are subject to national
legislative framework conditions. In the case of appli-
cations involving applicants of different nationalities,
full counts have been applied.
15
In total, we observed patent activity in the field
of stem cell technology for 27 countries. Excluded
from our analysis were outliers (n=4): countries for
which the dependent variable (amount of patent
activity/capita) diverges more than 3 standard devia-
tions from the mean, resulting either from low num-
bers of patent (application) counts (Uruguay and
Czech Republic) or a small number of inhabitants
(e.g., Luxemburg, The Netherlands Antilles).
16
Assessing legislative framework conditions
For the countries in which significant technological
activity in the field of stem cell technology has been
identified, a content analysis of legislative framework
conditions on human stem cell research has been per-
formed. Legislative documents from a range of sour-
ces have been used.
17 After expert validation, the
following four dimensions have been used to charac-
terize human stem cell legislation on a national level
according to which activities were allowed at the
time: (1) R&D aimed at human reproductive cloning;
(2) R&D aimed at human therapeutic cloning; (3) pro-
curement of human stem cells from supernumerary
embryos for R&D; and (4) use of human adult stem
cells for R&D.
Each country obtained a score on these four dimen-
sions. Scores of 0 and 1 were given if legislation ex-
plicitly prohibited (0) or allowed (1) these activities.
In cases where no legislation pertaining to human
stem cell research existed or where legislation was
vague or ambiguous in terms of permitting human
stem cell research, a score of 2 was applied. Countries
were able to obtain different values for different years
if pertinent legislative changes occurred. After charac-
terizing all countries for which stem cell patent data
have been collected, two dimensions were dropped
from the analysis because of lack of variance: all coun-
tries under study explicitly banned research activities
pertaining to human reproductive cloning (1), whereas
all of them permitted the use of human adult stem cells
for research and development (4).
Modeling the relation between legislative
framework and technological activity
In order to assess the relation between human stem
cell legislative frameworks and technological activity
in the field of stem cells in general, we opted for an
analysis of (co)variance (ANCOVA). Technological
productivity—i.e., the number of patents on stem
11 Identified patents have been analyzed in terms of relevance
by two experts (B Sarkadi, Head of the Department of Cell
Metabolism at the National Institute of Haematology and
Immunology, Budapest, and International Research Scholar of
the Howard Hughes Medical Institute, USA, and C Verfaillie,
Director of the Stem Cell Institute, University of Minnesota
and Katholieke Universiteit Leuven).
12 Gla ¨nzel W, Verbeek A, Du Plessis M, Van Looy B, Mager-
man T, Thijs B, Schlemmer B, Debackere K, Veugelers R.
Stem cells: analysis of an emerging domain of scientific and
technological endeavour. Report by Steunpunt O&O Statis-
tieken. Leuven, Belgium: Katholieke Universiteit Leuven,
2004.
13 This search key implied a combination of terms (e.g., *stem
cell*; * ES cell* or *.ES cell* or -ES cell*; *progenitor cell* or
*hematopoi* cell*).
14 A semiautomated procedure was used to classify the patents.
If only the words ‘‘embryo’’ or ‘‘embryonic’’ were observed in
the title or abstract, the work was classified as category 1. For
category 2, the terms ‘‘adult’’ or ‘‘progenitor cell’’ were used,
excluding the terms ‘‘embryo/embryonic.’’ Patent documents
that combined both sets of keywordswere classified as category
3. The remaining patents were grouped in category 4. The out-
comes of this technique were validated by experts.
15 Applying a fractional count logic yields results similar to the
ones reported in this paper.
16 At the same time, it can be noted that results obtained without
excluding outliers are completely in line with the findings
reported in Table 4 below.
17 European Commission, Directorate General–Research: Sur-
vey on opinions from National Ethics Committees or similar
bodies, public debate, and national legislation in relation to
human embryonic stem cell research and use. Volume I: EU
Member States, July 2004; available at www.europa.eu.int/
comm/research/biosociety/bioethics/documents_en.htm; Vol-
ume II: Countries associated to FP6 and Third Countries,
July 2004; available at www.europa.eu.int/comm/research/
biosociety/bioethics/documents_en.htm; Database of Global
Policies on Human Cloning and Germ-Line Engineering; avail-
able at www.glphr.org/genetic/genetic.htm or www.mbbnet
.umn.edu/scmap.html
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dependent variable. We applied a logarithmic transfor-
mation in order to obtain a normal distribution. In ad-
dition to the two legislative dimensions (obtaining
human stem cells from supernumerary embryos and
R&D on human therapeutic cloning), the patent sys-
tem (USPTO/EPO), type of human stem cell research,
and status of the patent (granted/application) act as in-
dependent, categorical, variables. The R&D expendi-
tures per capita have been included as a covariate in
order to control for differences between countries in
terms of overall R&D intensity (source: Eurostat and
OECD).
18 It can be noted that R&D expenditures in
the field of biotechnology—or even stem cells—
would be a better control variable to assess the specific
impact of legislation. Because such detailed harmo-
nized statistics are not available for the majority of
countries under study, overall yearlyR&D expenditures
(divided by GDP) have been used. Given the specific
focus of this contribution, interaction effects between
thelegal variables as wellasbetween the legalvariables




Identification. In total, 1571 US patents, European
patents, and European patent applications related to
stem cell technology were identified for the period
1997–2003 (Table 1). For the US, 762 patents were
granted,whereasinEurope,asofApril2005,48patents
were granted and 761 applications were still pending.
Classification. In Europe as well as in the US, most
of the relevant documents (patents and patent applica-
tions) relate to adult stem cells (Table 2). Likewise,
most granted European patents pertain to adult stem
cells. Although in Europe, compared with the US, a
higher number of patent documents refer to embryonic
stem cells, these are mainly applications.
Assignment of patents to countries. In total, 27 na-
tionalities were identified for the assignees in the data-
set compiled with the search key outlined. Significant
technological activity was identified for 23 countries,
which were withheld for further analysis. A few outli-
ers (n=4) have been excluded from the analysis
(see supra). The countries under study are Austria,
Australia, Belgium, Canada, China, Czech Republic,
Denmark, France, Germany, India, Israel, Italy, Japan,
Norway,RepublicofKorea,Singapore,Spain,Sweden,
Switzerland, Taiwan, The Netherlands, United King-
dom, and United States. In total, 1394 patents and
patent applications were held forfurther analysis.
Legislative framework conditions
Out of the 23 countries under study up to 2004, 10
did not provide any clear national legislation on
human stem cell research. Of the remaining countries,
seven banned obtaining hESCs from supernumerary
embryos at the beginning of our observations. Within
the observation period, eight countries changed their
legislation to allow use of hESCs from supernumer-
ary embryos (Table 3). Three countries (Germany,
Austria, France) allow importation of hESC lines
under strict conditions. Eight countries started to
allow research in the field of therapeutic cloning
within the observed time. In the EU, only the UK
and Belgium allow cloning of human stem cells for
therapeutic or research purposes. Outside Europe,
countries with permissive laws include India (from
2002), Japan (from 2001), China (from 2004), Singa-
pore (from 2004), South Korea (from 2004), and
Israel (from 2002).
Table 2. Number of Patents and Patent Applications in
Each of Four Stem Cell Categories for 1997–2003










aMention of the isolation or use of embryonic stem cells in the title or
abstract.
bMention of the isolation or use of adult stem cells or progenitor cells
in the title or abstract.
cMention of the words ‘‘stem cell’’ in the title or abstract with no dis-
tinction made between adult and embryonic cells.
dFor example, techniques for culturing cells; e.g., different feeder
layers, growth factors, and hormones.
Table 1. Number of Stem Cell Patents Identified




1997–2003 USPTO 762 granted
1997–2003 EPO 809 applications (of which 48
had been granted
as of April 2005)
18 An alternative approach to accommodate differences in R&D
expenditures consists ofdividing the observedpatentactivity by
R&D expenditures and uses the obtained measure as a depen-
dent variable. In Appendix 1, the results obtained when adopt-
ing this approach can be found. As one can notice, the results
are in line with the findings reported in Table 4 below.
19 A full factorial model, including all interaction effects, yields
results similar to the ones reported here.
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and technological activity
Table 4 provides an overview of the results obtained
by ANCOVA. As mentioned, several control variables
have been introduced into the model. The findings
pertaining to these control variables will be discussed
first.
As becomes apparent when inspecting Table 2,
most patent activity is observed for adult stem cells.
The observed differences turn out to be statistically
significant when looking at normalized patent data
as well (P<0.05). Productivity of countries was signif-
icantly higher within the EPO system than the USPTO
system (p=0.001). The difference between applica-
tions and grants is significant (p<0.001) in favor of
applications. Finally, a significant and positive differ-
ence with regard to the R&D intensity of a national in-
novation system is observed; overall, more R&D
expenditures (per GDP) coincide with more stem
cell-oriented technological activity.
Both legislative framework conditions under study
significantly influence the amount of technological ac-
tivity observed (p<0.001). For countries with more
permissive legislation—both with respect to obtaining
human stem cells from supernumerary embryos and
R&D on human therapeutic cloning—significantly
more patent activity is observed, as can be seen by
inspecting Table 5. Countries where the legislation ex-
plicitly allows obtaining human ESCs from supernu-
merary embryos display technological productivity
figures 2.5· to 3· higher than countries constraining
this type of research. Countries that permit R&D on
human therapeutic cloning also show more techno-
logical productivity, although the difference is less
pronounced (15% to 20%).
20
Our analysis did not reveal a significant interaction
between the two legislative conditions under study.
Likewise, no differential effects of different types of
stem cell research were observed, implying that the
presence ofbothlegislative frameworks affectstechnol-
ogy development to a similar degree for all types of
stem cells.
Table 3. Number of Countries in Each Category of Legislation on Stem Cell Research
Not allowed Allowed Vague/ambiguous legislation
Legislation Pre 2000 Post 2004 Pre 2000 Post 2004 Pre 2000 Post 2004
Obtaining stem cells from
supernumerary embryos
7 261 8 1 0 3
R&D on therapeutic cloning 20 12 0 8 3 3






square F P value
Corrected model 35.825
a 23 1.558 8.804 0.000
Intercept 5.429 1 5.429 30.683 0.000
Patent system (EPO/USPTO) 1.722 1 1.722 9.735 0.002
Issued (Y/N) 5.790 1 5.790 32.724 0.000
Type of stem cells 1.675 3 0.558 3.155 0.025
Obtaining stem cells from supernumerary embryos allowed 5.666 2 2.833 16.012 0.000
R&D on therapeutic cloning allowed 6.614 2 3.307 18.691 0.000
R&D intensity 1.003 1 1.003 5.667 0.018
R&D on therapeutic cloning allowed* obtaining stem
cells from supernumerary embryos allowed
0.426 1 0.426 2.409 0.122
Type of stem cells* R&D on therapeutic cloning allowed 1.837 6 0.306 1.730 0.114
Type of stem cells* obtaining stem cells from
supernumerary embryos allowed
0.683 6 0.114 0.644 0.695
Error 48.478 274 0.177
Total 139.92 298




20 Although these differences are to a large extentattributable to
differences between countries (which did not change their leg-
islation during the observed time period), within-country differ-
ences have been observed for a number of countries (e.g.,
Australia, Israel, Netherlands). Inspecting these cases in detail
systematically reveals an increase in technological productivity
when adopting a more permissive legislative stance.
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Promising advances in stem cell research have been
accompanied by ethical concerns that have been trans-
lated differently in national regulations invarious coun-
tries. In this analysis, we investigated whether
legislative research frameworks affect the amount and
natureof technological development activities within
different national innovation systems. Our findings
revealed that stem cell research legislation does affect
technological activities in a significant manner. Coun-
tries with relatively flexible research legislation, such
as Singapore, Taiwan, Spain, China, Belgium, UK,
and Japan,display higher levelsof technological activ-
ity (normalized by population). Research legislation,
especially that which allows and defines the use of
human stem cells harvested from supernumerary em-
bryos, clearly influences the technological productiv-
ity of a particular territory. Overall, our findings
suggest that technology trajectories are modulated
by research legislation.21
Table 5. Average Observed Patent Activity

















21 Rip A, Misa T, Schot J. Managing Technology in Society:
The Approach of Constructive Technology Assessment.N e w
York: Pinter Publishers, 1995; Vob J-P, Bauknecht D, Kemp
R. Reflexive Governance for Sustainable Development. Chel-
tenham, UK: Edgar Elgar, 2006.
APPENDIX 1: ANCOVA RESULTS: PATENTS/R&D EXPENDITURES
ACTING AS DEPENDENT VARIABLE
The following table reports the findings obtained
when using patent activity divided by R&D expendi-
tures as a dependent variable. Although the majority
of the relations are in line with the findings reported
in the body of the paper, the interaction between
legislation pertaining to therapeutic cloning and
type of stem cells becomes significant. In countries
where therapeutic cloning is not allowed, higher lev-
els of adult stem cell technological activity are ob-
served; where therapeutic cloning is allowed, higher
levels of embryonic stem cell research activity are
being observed.
Source Type III sum of squares df Mean square F P value
Corrected model 26353.879
a 23 1145.821 5.495 0.000
Intercept 5559.973 1 5559.973 26.665 0.000
Obtaining stem cells from supernumerary embryos allowed 7218.614 2 3609.307 17.310 0.000
R&D on therapeutic cloning allowed 3494.421 2 1747.210 8.379 0.000
Obtaining stem cells from supernumerary embryos allowed*
R&D on therapeutic cloning allowed
807.844 1 807.844 3.874 0.050
Type of stem cells 3454.716 3 1151.572 5.523 0.001
Patent system (EPO/USPTO) 262.994 1 262.994 1.261 0.262
Issued (Y/N) 1052.723 1 1052.723 5.049 0.025
R&D expenditures/GDP 837.790 1 837.790 4.018 0.046
R&D on therapeutic cloning allowed* type of stem cells 6435.478 6 1072.580 5.144 0.000
Obtaining stem cells from supernumerary
embryos allowed* type of stem cells
1642.099 6 273.683 1.313 0.252
Error 57132.144 274 208.511
Total 128550.563 298
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